Sharing the Results: ALKS 3831

Video

ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.

Adam Simmons, MPH, shares results and insights from the Enlightened II study for Alkermes' drug, ALKS 3831.

To read more about ALKS 3831, see FDA Advisory Committee Votes in Favor of ALKS 3831.

Mr Simmons is the Director of Clinical Program Management at Alkermes.

Related Videos
nicotine use
brain schizophrenia
schizophrenia
schizophrenia
exciting, brain
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
Related Content
Researchers investigated the effects of this supplementation on cognitive function and disease severity in schizophrenia. Here’s what they found.

Study Finds That Probiotics, Vitamin D May Enhance Cognitive Function in Schizophrenia

April 12th 2024
Article
Treating ‘Morally Objectionable’ Patients

Treating ‘Morally Objectionable’ Patients

September 27th 2021
Podcast
What is new in research on schizophrenia?

Schizophrenia Research Roundup: April 12, 2024

April 12th 2024
Article
More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

May 11th 2021
Podcast
From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

The Week in Review: March 18-22

March 23rd 2024
Article
The trial aims to investigate the positive, negative, and cognitive domains of schizophrenia.

First Patient Screened Ahead of Schedule in Phase 2 Clinical Trial of Therapeutic Candidate for Schizophrenia

March 21st 2024
Article
© 2024 MJH Life Sciences

All rights reserved.